Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of F-652 with a Single Dose in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs F 652 (Primary)
- Indications Alcoholic hepatitis
- Focus Adverse reactions; First in man
- Sponsors Generon (Shanghai) Corporation
- 04 May 2015 Positive results published in a Generon (Shanghai) Corporation media release.
- 04 May 2015 Status changed from not yet recruiting to completed, as reported in a Generon (Shanghai) Corporation media release.
- 07 Jan 2015 New trial record